Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.33)
# 348
Out of 5,182 analysts
142
Total ratings
53.73%
Success rate
16.59%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $8 → $10 | $3.49 | +186.53% | 8 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $135 → $140 | $104.04 | +34.56% | 2 | Feb 27, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $150 → $100 | $15.23 | +556.60% | 8 | Feb 27, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $92.48 | +40.57% | 7 | Dec 8, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $6.32 | +295.57% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $128.64 | +55.47% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.91 | +930.93% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $74.52 | +47.61% | 13 | Oct 30, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.46 | +584.93% | 1 | Oct 6, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $66.82 | +12.24% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.94 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $25.07 | -0.26% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $14.27 | +75.19% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $8.89 | -32.51% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $226.66 | +23.53% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $5.52 | +805.80% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $10.75 | +86.05% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $272.75 | -21.17% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.67 | +87.27% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.41 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $7.95 | +277.36% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.45 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.35 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $38.62 | +133.04% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.93 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $135.98 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $73.60 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.30 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.10 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $115.07 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $8.78 | +1,266.74% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $54.26 | +19.79% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $19.15 | -42.56% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $128.04 | +1.53% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $744.44 | +2.09% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $28.56 | -47.48% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $13.25 | +315.09% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.56 | +1,823.08% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.47 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.62 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $520.09 | -51.93% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $95.72 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $72.23 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.76 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $17.90 | +22.91% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $16.81 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $53.81 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $197.38 | -51.87% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $3.49
Upside: +186.53%
Nuvalent
Feb 27, 2026
Maintains: Overweight
Price Target: $135 → $140
Current: $104.04
Upside: +34.56%
Janux Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $150 → $100
Current: $15.23
Upside: +556.60%
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $92.48
Upside: +40.57%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $6.32
Upside: +295.57%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $128.64
Upside: +55.47%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.91
Upside: +930.93%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $74.52
Upside: +47.61%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.46
Upside: +584.93%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $66.82
Upside: +12.24%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $19.94
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $25.07
Upside: -0.26%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $14.27
Upside: +75.19%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $8.89
Upside: -32.51%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $226.66
Upside: +23.53%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $5.52
Upside: +805.80%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $10.75
Upside: +86.05%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $272.75
Upside: -21.17%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.67
Upside: +87.27%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.41
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $7.95
Upside: +277.36%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $9.45
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.35
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $38.62
Upside: +133.04%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $135.98
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $73.60
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.30
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.10
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $115.07
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $8.78
Upside: +1,266.74%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $54.26
Upside: +19.79%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $19.15
Upside: -42.56%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $128.04
Upside: +1.53%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $744.44
Upside: +2.09%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $28.56
Upside: -47.48%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $13.25
Upside: +315.09%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.56
Upside: +1,823.08%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.47
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.62
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $520.09
Upside: -51.93%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $95.72
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $72.23
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.76
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $17.90
Upside: +22.91%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $16.81
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $53.81
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $197.38
Upside: -51.87%